Target intelligence / Profile preview

Agglutinin-like sequence 3 (Als3)

Target
Als3
Molecular classification
Cell wall protein, Adhesin, Invasin, GPI-anchored protein, Glycoprotein
01

Overview

Agglutinin-like sequence 3 (Als3) is a critical cell surface protein and virulence factor of the opportunistic fungal pathogen Candida albicans. It belongs to the Als family of adhesins and is uniquely expressed during the hyphal phase of the fungus. Als3 functions as both an adhesin, mediating attachment to various host substrates, and an invasin, inducing its own endocytosis by host epithelial and endothelial cells through molecular mimicry of host cadherins such as E-cadherin and N-cadherin. Beyond its role in tissue invasion, Als3 is essential for biofilm formation on medical devices and facilitates iron acquisition from host ferritin. Due to its surface accessibility and central role in pathogenesis, Als3 is a primary target for immunotherapeutic development, including the NDV-3A vaccine, which has shown promise in clinical trials for preventing recurrent vulvovaginal candidiasis and systemic fungal infections.

Other names
Als3pALS3Agglutinin-like protein 3Candida albicans Als3
02

Mechanism of action

Vaccination with the recombinant N-terminal domain of Als3 (rAls3p-N) induces high titers of anti-Als3 antibodies and a robust Th1/Th17 cellular immune response. These antibodies block the fungal protein's ability to adhere to and invade host tissues. Monoclonal antibodies like MAbC7 directly bind to the N-terminal domain of Als3, preventing its interaction with host receptors like E-cadherin and N-cadherin, thereby inhibiting fungal endocytosis and tissue damage.

03

Biological functions

AdhesionInvasionEndocytosis inductionBiofilm formationIron acquisitionHost cell interaction
04

Disease associations

CandidiasisOropharyngeal candidiasisVulvovaginal candidiasisSystemic candidiasisInfection
05

Safety considerations

Potential for cross-reactivity with host proteinsInjection site reactions (vaccine)Immune-mediated side effects
06

Interacting drugs

NDV-3A

3 more in the full profile.

07

Biomarkers

Anti-Als3 antibody titersTh1/Th17 cytokine levels (IFN-gamma, IL-17)

Beyond the preview

Go deeper on Agglutinin-like sequence 3 (Als3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agglutinin-like sequence 3 (Als3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call